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Abstract
Background Clinical management of heart failure
with preserved ejection fraction (HFpEF) centres on
treating comorbidities and is likely to vary between
countries. Thus, to provide insight into the current
management of HFpEF, studies from multiple coun-
tries are required. We evaluated the clinical profiles
and current management of patients with HFpEF in
the Netherlands.
Methods We included 2153 patients with HFpEF (de-
fined as a left ventricular ejection fraction ≥50%) from
the CHECK-HF registry, which included patients from
2013 to 2016.
Results Median age was 77 (IQR 15) years, 55% were
women and the most frequent comorbidities were hy-
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pertension (51%), renal insufficiency (45%) and atrial
fibrillation (AF, 38%). Patients between 65 and 80 years
and those over 80 years had on average more comor-
bidities (up to 64% and 74%, respectively, with two
or more comorbidities) than patients younger than
65 years (38% with two or more comorbidities, p-
value <0.001). Although no specific drugs are available
for HFpEF, treating comorbidities is advised. Beta-
blockers were most frequently prescribed (78%), fol-
lowed by loop diuretics (74%), renin-angiotensin sys-
tem (RAS) inhibitors (67%) and mineralocorticoid re-
ceptor antagonists (MRAs, 39%). Strongest predictors
for loop-diuretic use were older age, higher New York
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What’s new?
 This study provides insight into the medi-
cal management of patients with heart failure
with preserved ejection fraction (HFpEF) in the
Netherlands.
 Additionally, this study demonstrates that the
prescription of beta-blockers, renin-angiotensin
system inhibitors and mineralocorticoid recep-
tor antagonists in HFpEF patients is primarily
determined by age, sex, New York Heart Associa-
tion (NYHA) class and underlying comorbidities.
 The newly gained insight into the effects of age,
sex, NYHA class and comorbidities might aid
heart failure specialists in optimising the man-
agement of HFpEF.
Conclusion The medical HFpEF profile is determined
by the underlying comorbidities, sex and age. Comor-
bidities are highly prevalent in HFpEF patients, espe-
cially in elderly HFpEF patients. Despite the lack of
evidence, many HFpEF patients receive regular beta-
blockers, RAS inhibitors and MRAs, often for the treat-
ment of comorbidities.
Keywords Heart failure with preserved ejection
fraction · HFpEF · Comorbidities · Treatment
Introduction
A large proportion of all heart failure (HF) patients are
diagnosed with HF with preserved ejection fraction
(HFpEF), with a further increase expected [1–3]. The
literature reports an estimated proportion of HFpEF
among HF patients of up to 50%, but that percent-
age is likely to be an underestimation, as many HF-
pEF patients go unrecognised, especially in primary
care [1]. HFpEF is associated with substantial mor-
bidity and mortality, comparable to HF with reduced
ejection fraction (HFrEF) [4], with an estimated 1-year
survival after the diagnosis of 78% [5]. HFpEF patients
more often have more comorbidities and are older
than HFrEF patients [6–8]. So far, there are no ev-
idence-based treatment options for HFpEF patients.
Recently, sacubitril-valsartan was not found to have
better primary clinical outcomes than valsartan in the
treatment of HFpEF [9], despite a large subset of hy-
pertensive patients and a significant blood-pressure-
lowering effect. Furthermore, the Swedish Heart Fail-
ure registry demonstrated the prognostic impact of
non-cardiac comorbidities [6], and European Society
of Cardiology (ESC) guidelines currently recommend
that only co-existing comorbidities be treated in HF-
pEF patients [4].
Despite the lack of specific treatment recommen-
dations, many HFpEF patients receive HFrEF medi-
cation [10]. However, whether the patient’s clinical
profile, such as age and sex, as well as the presence
of comorbidities influences the medical management
of HFpEF patients remains unclear. With the current
analysis of 2153 HFpEF patients in the Dutch registry
CHECK-HF (Chronisch Hartfalen ESC-richtlijn Car-
diologische praktijk Kwaliteitsproject-HartFalen), we
aimed to investigate whether the clinical profile and
comorbidities influence the contemporary manage-
ment of HFpEF patients.
Methods
Study population
The CHECK-HF is a cross-sectional registry consist-
ing of unselected patients from 34 Dutch hospitals
with the diagnosis of chronic HF, according to ESC-
guideline definitions, treated at Dutch dedicated out-
patient HF clinics (96%) in the period September 2013
to September 2016. The registry comprises 10,910 pa-
tients with chronic HF [11, 12] and includes detailed
data on baseline characteristics, electrocardiography,
echocardiography and laboratory assessments. De-
tails of the design of the registry were published pre-
viously [11].
Patients were included if they were 18 years or older
and had a diagnosis of HF based on the 2012 ESC
guidelines: i.e. structural and/or functional cardiac
abnormalities, signs and symptoms of HF [13]. Base-
line ejection fraction was assessed by echocardiogra-
phy. HFpEF was classified as a left ventricular ejection
fraction (LVEF) of ≥50% with no previously known re-
duced LVEF. In total, 2267 (21.3%) patients in the
registry were classified as HFpEF patients. HFpEF pa-
tients in whom no data on drug treatment had been
recorded (n=114) were excluded. Therefore, a total of
2153 HFpEF patients were included in this analysis.
This study was conducted in accordance with the
Helsinki declaration and was approved by the Medical
Ethics Committee 2017at Maastricht University Med-
ical Centre (Maastricht, the Netherlands).
Baseline measurements
Baseline variables used in the analyses are described
in detail in the design article [11]. For the analysis of
comorbidities, we focused on atrial fibrillation (AF),
diabetes mellitus (DM), hypertension, hypercholes-
terolaemia, renal insufficiency (estimated glomerular
filtration rate (eGFR) <60ml/min or a documented
history of renal insufficiency), thyroid dysfunction,
peripheral artery disease (PAD), iron deficiency and
chronic obstructive pulmonary disease (COPD). AF
was defined as a documented history of AF or AF
diagnosed by 12-lead electrocardiogram, performed
during the most recent outpatient clinic visit.
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Table 1 Baseline patient characteristics, stratified by age and sex
Men Women
Overall <65 years 65–80 years >80 years <65 years 65–80 years >80 years p-value
Number 2153 204 452 321 144 453 571
Age (years), median (IQR) 77 (69–84) 58 (53–61) 72 (69–77) 84 (82–87) 58 (52–62) 74 (70–77) 85 (82–88) <0.001
History of coronary artery
disease
513 (24.6) 67 (33.2) 171 (38.6) 83 (26.7) 29 (20.9) 84 (19.1) 79 (14.3) <0.001
History of cancer 242 (14.1) 10 (5.7) 59 (16.0) 54 (21.1) 17 (13.7) 48 (13.2) 54 (12.4) <0.001
History of valvular disease 207 (15.6) 9 (9.8) 45 (16.1) 32 (13.3) 14 (19.4) 55 (20.7) 52 (13.8) 0.067
Heart failure measures (%)
Ischaemic aetiology HF 612 (29.3) 72 (35.6) 199 (44.9) 108 (34.7) 35 (25.2) 99 (22.5) 99 (17.9) <0.001
NYHA class
NYHA I 418 (19.8) 75 (37.9) 122 (27.3) 36 (11.4) 49 (34.3) 75 (16.7) 61 (10.9)
NYHA II 1038 (49.1) 91 (46.0) 224 (50.1) 173 (54.6) 63 (44.1) 224 (50.0) 263 (47.0)
NYHA III 612 (29.0) 30 (15.2) 93 (20.8) 98 (30.9) 31 (21.7) 145 (32.4) 215 (38.4)




















BMI (kg/m2) 28.4± 5.9 29.3± 6.4 29.0± 5.5 26.8± 4.5 29.5± 7.6 30.0± 6.5 27.3± 5.3 <0.001
Pulse pressure 62.1± 19.2 58.3± 14.7 62.7± 18.8 60.7± 18.3 58.1± 18.7 63.7± 19.9 63.7± 20.7 <0.001
DBP (mmHg) 72.7± 12.2 78.9± 13.2 73.8± 11.1 69.2± 11.4 76.7± 11.5 72.9± 12.4 70.4± 12.0 <0.001
SBP (mmHg) 134.8± 22.9 137.2± 22.2 136.5± 22.3 129.9± 21.8 134.8± 21.6 136.5± 23.5 134.2± 23.5 <0.001
eGFR 61.3± 25.3 75.5± 21.2 57.7± 23.5 49.0± 24.7 68.4± 21.2 54.6± 21.5 45.2± 19.4 <0.001
Oedema (%) 292 (17.9) 23 (13.5) 58 (16.5) 53 (22.0) 19 (15.6) 54 (15.7) 85 (21.0) 0.086
Devices (%) 346 (16.1) 31 (15.2) 66 (14.6) 55 (17.1) 17 (11.8) 74 (16.3) 103 (18.0) 0.454
Comorbidities (%)
Hypertension 1085 (50.6) 90 (44.1) 214 (47.3) 153 (47.7) 66 (45.8) 240 (53.0) 322 (56.4) 0.006
Diabetes 642 (29.9) 45 (22.1) 159 (35.2) 69 (21.5) 32 (22.2) 183 (40.4) 154 (27.0) <0.001
COPD 109 (19.1) 22 (10.8) 101 (22.3) 79 (24.6) 27 (18.8) 87 (19.2) 93 (16.3) 0.001
Hypercholesterolaemia 236 (11.0) 28 (13.7) 49 (10.8) 32 (10.0) 17 (11.8) 64 (14.1) 46 (8.1) 0.041
Renal insufficiencya 972 (45.3) 22 (10.8) 164 (36.3) 198 (61.7) 29 (20.1) 203 (44.8) 356 (62.3) <0.001
Atrial fibrillation 817 (38.4) 33 (16.3) 175 (38.9) 152 (47.5) 17 (12.1) 162 (35.9) 278 (49.2) <0.001
Thyroid dysfunction 167 (8.4) 7 (3.7) 18 (4.2) 15 (5.0) 16 (11.9) 51 (12.1) 60 (11.5) <0.001
Peripheral artery disease 71 (3.6) 4 (2.1) 16 (3.8) 13 (4.3) 3 (2.2) 19 (4.5) 16 (3.1) 0.568
Iron deficiency 11 (0.6) 0 (0.0) 2 (0.5) 1 (0.3) 0 (0.0) 5 (1.2) 3 (0.6) 0.392
Number of comorbidities
(median (IQR))
2 (1–3) 1 (0–2) 2 (1–3) 2 (1–3) 1 (0–2) 2 (1–3) 2 (2–3) <0.001
IQR interquartile range, HF heart failure, NYHA New York Heart Association, NTproBNP N-terminal pro-B-type natriuretic peptide, BMI body mass index, DBP
diastolic blood pressure, SBP systolic blood pressure, eGFR estimated glomerular filtration rate, COPD chronic obstructive pulmonary disease
aDefined as an eGFR <60ml/min or a documented history of renal insufficiency
Statistical analyses
Baseline continuous variables are presented asmean±
standard deviation or median with interquartile range
(IQR) where appropriate; categorical data are pre-
sented as numbers and percentages. A chi-square
test was used to compare data for categorical vari-
ables and a t-test or Mann-Whitney U test for con-
tinuous data. Additionally, baseline characteristics
were analysed in age and sex strata (men <65 years,
men 65–80 years, men >80 years, women <65 years,
women 65–80 years, and women >80 years). We in-
vestigated the distribution for the number of comor-
bidities, which was categorised into no comorbidities,
one, two, or three or more comorbidities, stratified by
age and sex (men <65 years, men 65–80 years, men
>80 years, women <65 years, women 65–80 years,
and women >80 years).
Missing data in the baseline measurements (Elec-
tronic Supplementary Material, Table S1) were im-
puted, using multiple imputation, from the mice al-
gorithm in the statistical software package R. Analyses
were performed on the ten imputed datasets sepa-
rately and results were pooled using Rubin’s rules.
Multivariable predictors of use of loop diuretics, beta-
blockers, renin-angiotensin system (RAS) inhibitors
and mineralocorticoid receptor antagonists (MRAs)
were assessed using multivariable logistic regression
Clinical profile and contemporary management of patients with heart failure
Original Article
Fig. 1 Percentage of pa-
tients per number of comor-
bidities, stratified by age
and sex (men <65 years,
men 65–80 years, men
>80 years, women<65 years,
women 65–80 years and
women >80 years)
analysis. All predictors of medication use in univari-
ate analysis (data not shown) at a p-value of <0.1
were included, using the enter method, in the mul-
tivariable regression analysis. Results are presented
as odds ratio and 95% confidence interval. Analy-
ses were performed using SPSS Statistical Package




Baseline characteristics are shown in Tab. 1. Overall,
the median age of the HFpEF patients was 77 years
(IQR 69–84 years), 54.5% were women and 24.6%
had a history of coronary artery disease. Comor-
bidities were frequently present at baseline, patients
had a median of 2 (IQR 1–3) comorbidities, and only
11.4% had no comorbidities. Renal insufficiency
(45.3%), hypertension (50.7) and AF (38.4%) occurred
most frequently.
Distribution of comorbidities
Fig. 1 shows the distribution for the number of co-
morbidities ranging from 0 to 3 or more, stratified by
age and sex. The younger patients aged <65 years,
both men and women, mainly had 0 or 1 comorbid-
ity, whereas older patients more often had 2 or more
comorbidities. Women had 3 or more comorbidities
more often than men (p=0.001).
Medical profile of HFpEF patients
The pharmacological therapy in HFpEF patients is
shown in Tab. 2 and is stratified according to age
categories, sex, and the presence of hypertension,
AF and DM. Loop diuretics were the most frequently
prescribed type of HF medication (79.4%), followed
by beta-blockers (78.4%), RAS inhibitors (67.3%) and
MRAs (38.5%). MRAs, diuretics, digoxin and oral
anticoagulants (OACs) were used most often in the
oldest age category (p<0.001 for all trends). Diuretics
(p<0.001), digoxin (p=0.002) and OACs (p<0.001)
were used more often in women than in men. HFpEF
patients with hypertension received RAS inhibitors
(p<0.001) and diuretics (p=0.016) more often than
patients without hypertension. MRAs (p<0.001), di-
uretics (p<0.001), digoxin (p<0.001), amiodarone
(p= 0.010), OACs (p<0.001) and non-vitamin K OACs
(p<0.001) were prescribed more often to HFpEF pa-
tients with AF. Diuretics and statins were prescribed
more often to HFpEF patients with DM (p<0.001, for
both). MRAs (p= 0.005), diuretics (p<0.001) and OACs
(p= 0.001) were prescribedmore often in patients with
clinical signs of congestion, while RAS inhibitors were
prescribed less often in these patients.
Fig. 2 Diuretics profile of patients with heart failure (HF) with
preserved ejection fraction. NYHANewYork Heart Association
Clinical profile and contemporary management of patients with heart failure
Original Article
Table 2 Profile of medication received by patients with heart failure with preserved ejection fraction
Diuretics RAS inhibitor Beta-blocker MRA Digoxin Amiodarone OAC NOAC Statin
Overall population 1710 (79.4) 1450 (67.3) 1685 (78.3) 828 (38.5) 388 (18.0) 98 (12.8) 1104 (59.2) 79 (4.2) 1754 (81.5)
Subgroups
Age
<65 years 183 (52.4) 240 (68.8) 273 (78.2) 100 (28.7) 40 (11.5) 8 (11.3) 99 (39.3) 9 (3.6) 314 (90.0)
65–80 years 709 (78.2) 653 (72.0) 720 (79.4) 329 (36.3) 164 (18.1) 51 (17.8) 459 (57.2) 34 (4.2) 786 (86.7)
>80 years 816 (91.2) 555 (62.0) 691 (77.2) 399 (44.6) 183 (20.4) 39 (9.6) 545 (67.5) 36 (4.5) 653 (73.0)
p-value <0.001 <0.001 0.534 <0.001 0.001 0.006 <0.001 0.831 <0.001
Sex
Men 725 (74.2) 658 (67.3) 767 (78.5) 353 (36.1) 148 (15.1) 36 (11.9) 463 (54.4) 32 (3.8) 829 (84.9)
Women 980 (83.8) 787 (67.3) 915 (78.2) 471 (40.3) 239 (20.4) 61 (13.3) 636 (63.2) 47 (4.7) 920 (78.6)
p-value <0.001 0.967 0.866 0.050 0.002 0.568 <0.001 0.334 <0.001
Hypertension
With HT 890 (81.5) 781 (71.5) 870 (79.7) 406 (37.2) 189 (17.3) 54 (12.7) 580 (61.4) 35 (3.7) 881 (80.7)
Without HT 820 (77.3) 669 (63.1) 815 (76.8) 422 (39.8) 199 (18.8) 44 (13.0) 524 (57.0) 44 (4.8) 873 (82.3)
p-value 0.016 <0.001 0.108 0.216 0.382 0.901 0.056 0.245 0.338
Atrial fibrillation
With AF 767 (93.3) 543 (66.1) 662 (80.5) 410 (49.9) 293 (35.6) 31 (9.1) 678 (86.3) 51 (6.5) 623 (75.8)
Without AF 931 (70.9) 899 (68.4) 1,010 (76.9) 410 (31.2) 90 (6.8) 64 (15.3) 415 (39.1) 28 (2.6) 1120 (85.2)
p-value <0.001 0.257 0.045 <0.001 <0.001 0.010 <0.001 <0.001 <0.001
Diabetes mellitus
With DM 567 (87.9) 445 (69.0) 509 (78.9) 267 (41.4) 123 (19.1) 27 (11.1) 342 (60.6) 18 (3.2) 560 (86.8)
Without DM 1143 (75.8) 1005 (66.6) 1176 (78.0) 561 (37.2) 265 (17.6) 71 (13.6) 762 (55.7) 61 (4.7) 1194 (79.2)
p-value <0.001 0.287 0.632 0.067 0.408 0.323 0.488 0.134 <0.001
Congestiona
With congestion 257 (88.0) 173 (59.2) 226 (77.4) 113 (38.7) 53 (18.2) 16 (12.1) 172 (64.4) 7 (2.6) 231 (79.1)
Without congestion 9689 (72.0) 937 (69.7) 1042 (77.5) 406 (30.2) 217 (16.1) 71 (12.7) 632 (52.9) 54 (4.5) 1059 (78.7)
p-value <0.001 0.001 0.978 0.005 0.400 0.851 0.001 0.161 0.887
RAS renin-angiotensin system, MRA mineralocorticoid receptor antagonist, OAC oral anticoagulant, NOAC non-vitamin K OAC, HT hypertension, AF atrial fibrilla-
tion, DM diabetes mellitus
aIndicated by either peripheral oedema or other signs of a hypervolaemic status
The distribution of all diuretic use, stratified ac-
cording to age categories, sex, New York Heart As-
sociation (NYHA) class and HF duration is shown in
Fig. 2. Diuretics were prescribed more often in older
patients, women, patients in a higher NYHA class, and
in patients who had been more recently diagnosed
with HF (p<0.001).
Determinants of drug therapy
Independent predictors of the use of loop diuretics,
RAS inhibitors, beta-blockers and MRAs are shown in
the Electronic Supplementary Material (Figs. S1–S4).
Older age, higher NYHA class, higher body mass
index (BMI), valvular disease, AF, COPD, DM and
concomitant treatment with MRAs and digoxin were
all positively associated with loop-diuretic use (Fig.
S1) with only higher mean arterial pressure negatively
associated with loop-diuretic use. In contrast, lower
eGFR and COPD were negatively associated with RAS-
inhibitor use (Fig. S2), while hypertension, statin and
diuretic use were independent predictors for RAS-
inhibitor use. Ischaemic aetiology, higher mean ar-
terial pressure, BMI >30kg/m2, digoxin and statin
use were positively associated with beta-blocker use,
while a higher heart rate was a negative predictor (Fig.
S3). Lastly, independent predictors for MRA use were:
higher NYHA class, lower eGFR, lower mean arterial
pressure, AF, valvular disease, PAD, statin and diuretic
use (Fig. S4).
Discussion
In this large contemporary HFpEF cohort, we demon-
strated that in daily clinical practice many HFpEF
patients receive similar treatment to HFrEF patients,
while such treatments are only evidence-based in the
latter group [12]. Compared to the HFrEF patient
[12], HFpEF patients are older, more often female,
and a large proportion of patients have a high num-
ber of comorbidities. Pharmacological therapy in
HFpEF patients is primarily determined by age, sex,
NYHA class and underlying comorbidities, such as
renal insufficiency, AF and hypertension.
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HFpEF and comorbidities
The CHECK-HF registry included a large number of el-
derly persons and a high percentage of women, with
many comorbidities, a patient population compara-
ble with current practice in other Western European
countries [8, 10, 14]. As in previous reports, AF, renal
insufficiency, diabetes and hypertension are the most
common reported comorbidities in HFpEF patients
[6, 15, 16]. Our results confirm that comorbidities are
more prevalent with increasing age [17].
Clarification of the distribution of comorbidities in
HFpEF patients is important, since it has been shown
that HFpEF patients could be differentiated into sev-
eral subgroups, based on comorbidities and other
clinical parameters [18]. It has been shown that these
HFpEF subgroups have significant differences in HF
prognosis [18]. Some beneficial effects of treatments
recommended for HFpEF patients have been demon-
strated in specific HFpEF subgroups, suggesting that
an HFpEF phenotype-specific treatment strategy may
be warranted [19].
Drug therapy prescribed to HFpEF patients
Despite the lack of guideline-recommended treatment
for HFpEF patients [4], the prescription rates of beta-
blockers and RAS inhibitors were high in the CHECK-
HF registry, similar to other European cohorts [8, 10,
14]. These medications were most likely prescribed
for the treatment of comorbidities, such as hyperten-
sion and AF. Similarly, many HFpEF patients received
loop diuretics, which were most likely prescribed to
treat congestion, as recommended by the HF guide-
lines [4]. Multivariable analysis showed that the most
important determinants of the medication profile are
the presence of hypertension, congestion and a higher
NYHA class.
The results from the Swedish Heart Failure Reg-
istry, demonstrating a reduced all-cause mortality in
HFpEF patients treated with beta-blockers compared
with patients without beta-blockers, might have influ-
enced physicians in prescribing beta-blockers in HF-
pEF patients. [20]. Additionally, a recent Cochrane re-
view, including 1046 patients from three randomised
controlled trials, demonstrated a significant reduc-
tion in all-cause mortality, but no reduction in HF-
related hospitalisations [21], although the findings of
the Cochrane review could not have influenced our
results.
Hypothetically, physicians might have been in-
fluenced to prescribe MRAs to reduce left ventric-
ular remodelling and fibrosis in HFpEF patients, as
a recent Cochrane review demonstrated a beneficial
effect of MRAs in preventing HF hospitalisations in
HFpEF patients [21]. Furthermore, a post hoc analy-
sis of the TOPCAT trial, investigating spironolactone,
showed regional differences between the Americas
and Russia/Georgia, indicating that MRAs might have
beneficial effects on mortality in the former [22].
Randomised trials investigating the effects of RAS in-
hibitors in HFpEF patients did not show a reduction
in mortality or HF-related hospitalisations [21]. Most
of these trials were underpowered or could have been
biased due to the large heterogeneity of the HFpEF
population. In contrast, some observational studies
have demonstrated an association between RAS-in-
hibitor use and lower all-cause mortality in HFpEF
patients [23]. Importantly some of the HF drugs may
have been prescribed simply because patients were
diagnosed with HF (in this case HFpEF) and because
physicians (and possibly also their patients) felt that
the prescription of medication may confer prognostic
benefit.
Strengths and limitations
This study has several strengths. First, the CHECK-
HF registry is currently one of the largest European
heart failure registries. Another strength is the de-
tailed information on medication use and comorbidi-
ties. Third, this cohort included a large subset of HF-
pEF patients with a diagnosis according to ESC guide-
lines. A limitation of this study is the lack of follow-
up data. Therefore, no associations can be studied for
clinical outcomes or mortality. In addition, specific
reasons for prescribing medication were not recorded;
therefore, any conclusions remain speculative. Finally,
in a considerable number of patients, data on eGFR
were missing. Although multiple imputation was used
to adjust for the missing values, some bias might have
occurred.
Conclusion
We demonstrated that many of the 2153 HFpEF pa-
tients in this large contemporary cohort receive beta-
blockers, RAS inhibitors and MRAs. The prescription
of beta-blockers, RAS inhibitors and MRAs in HFpEF
patients is primarily determined by age, sex, NYHA
class and underlying comorbidities.
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